


Claims

1. A compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof:



wherein

A represents a structure represented by the following formula [2]:



wherein

R^{11} and R^{12} are the same or different and each represent a hydrogen atom or a halogen atom,


R^2 represents a hydrogen atom or C_{1-6} alkyl,

ring E represents pyrrole, furan, pyrazole, imidazole, isoxazole, oxazole, isothiazole, triazole, oxadiazole, tetrazole, pyridine, pyridazine, pyrimidine, or pyrazine,

R^{31} and R^{32} are the same or different and each represent a hydrogen atom, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, or mono- C_{1-6} alkylamino, and


W represents a single bond, the formula -NH-, the formula -O-, or the formula -CONH-, and

Y represents a hydrogen atom or any structure of the following formulas [3']:




wherein

Z¹ represents any structure of the following formula group [4']:




[4']

Z³ represents a structure of the following formula [4-a]:



L^2 , $L^{2'}$, $L^{2''}$, and $L^{2'''}$ are the same or different and each represent any structure of the following formula group [5]:




and

A' , A'' , and A''' each represent the same structure as the structure represented by A .


2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein

Y is a hydrogen atom or a structure represented by the following formula [3]:





wherein

Z^1 is any structure of the following formula group [4]:



and

L^2 and L^{2^1} are the same and are any structure of the following formula group [5]:




[5]

and

A' is the same structure as the structure represented by A.

3. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein

Y is a structure represented by the following formula [3]:









wherein

L², L^{2'}, Z¹, and A' are as defined above.

4. The compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, wherein


Z¹ is any structure of the following formula group [6]:



[6]

5. The compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein

the structure represented by the formula [2] is a structure of the following formula [7]:





wherein


ring E and W are as defined above.


6. The compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein

in the formula [7], the structure represented by the following formula [8] is any structure of the following formula group [9]:




7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof which is selected from the group consisting of the following compounds:







8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof which is represented by the following:



9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof which is represented by the following:



10. The compound according to claim 1 or a pharmaceutically acceptable salt thereof which is represented by the following:



11. A compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof for use as a medicament.

12. A NHE3 inhibitor comprising a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof as an active ingredient.

13. An intestinal water secretion promoter comprising a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof as an active ingredient.

14. Use of the compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of constipation.

15. A sodium absorption inhibitor comprising a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof as an active ingredient.

16. Use of the compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of hypertension.

17. Use of the compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of nephropathy.

18. Use of the compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of body fluid retention.

19. A phosphorus absorption inhibitor comprising a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof as an active ingredient.

20. Use of the compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of hyperphosphatemia.

21. Use of the compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of CKD-MBD.